Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 217 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR New on NCI Websites for December 2018 December 28, 2018 Sacituzumab Govitecan Demonstrates Significant Improvement in Survival in Heavily Pretreated, Locally... September 5, 2022 A Deep-Learning Model Predicts the Primary System Origin of Malignant Cells... April 26, 2024 The rise of the ‘long-waiter’ – why cancer waiting times are... November 10, 2022 Load more HOT NEWS T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic... FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for NSCLC with EGFR... UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation Should People Over Age 75 Be Screened for Colorectal Cancer?
